158 related articles for article (PubMed ID: 16208151)
21. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
22. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis.
Ichiki T; Izumi R; Cataliotti A; Larsen AM; Sandberg SM; Burnett JC
Peptides; 2013 Oct; 48():21-6. PubMed ID: 23927843
[TBL] [Abstract][Full Text] [Related]
23. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
24. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
[TBL] [Abstract][Full Text] [Related]
26. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
Pu Q; Schiffrin EL
Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
[TBL] [Abstract][Full Text] [Related]
27. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
28. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
Hayek T; Hamoud S; Keidar S; Pavlotzky E; Coleman R; Aviram M; Kaplan M
J Cardiovasc Pharmacol; 2004 Jan; 43(1):140-7. PubMed ID: 14668580
[TBL] [Abstract][Full Text] [Related]
29. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
30. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
Vesterqvist O; Reeves RA
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
[TBL] [Abstract][Full Text] [Related]
32. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
33. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Farina NK; Johnston CI; Burrell LM
J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
[TBL] [Abstract][Full Text] [Related]
34. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
Ying L; Flamant M; Vandermeersch S; Boffa JJ; Chatziantoniou C; Dussaule JC; Chansel D
Hypertension; 2003 Nov; 42(5):937-44. PubMed ID: 14569001
[TBL] [Abstract][Full Text] [Related]
35. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
Korshunov VA; Massett MP; Carey RM; Berk BC
J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
[TBL] [Abstract][Full Text] [Related]
36. Vasopeptidase inhibition with omapatrilat increases fluid and protein microvascular permeability in cat skeletal muscle.
Persson J; Morsing P; Grände PO
J Hypertens; 2004 Mar; 22(3):637-44. PubMed ID: 15076171
[TBL] [Abstract][Full Text] [Related]
37. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
38. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
39. Renoprotective effects of omapatrilat are mediated partially by bradykinin.
Zhou X; Ono H; Ono Y; Frohlich ED
Am J Nephrol; 2003; 23(4):214-21. PubMed ID: 12789027
[TBL] [Abstract][Full Text] [Related]
40. Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
Davidson EP; Coppey LJ; Holmes A; Yorek MA
Eur J Pharmacol; 2012 Feb; 677(1-3):180-7. PubMed ID: 22198047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
